Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes

Meunier Mathieu , Chloé Friedrich (1, 2) , Nicolas Ducrot , Johanna Zannoni , Tondeur Sylvie (3) , Nelly Jerraya , Sophie Rousseaux (4) , Florent Chuffart (4) , Olivier Kosmider , Zoubida KARIM (5) , Sophie Park (6)

1 IC UM3 (UMR 8104 / U1016) - Institut Cochin
2 Hôpital Cochin [AP-HP]
3 CHU - Centre Hospitalier Universitaire [Grenoble]
4 IAB - Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble)
5 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires
6 CHU Grenoble

Domains: Life Sciences [q-bio]

Meunier Mathieu, Chloé Friedrich, Nicolas Ducrot, Johanna Zannoni, Tondeur Sylvie, et al.. Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes. Annals of Hematology, 2022, 101 (12), pp.2633-2643. ⟨10.1007/s00277-022-04993-7⟩. ⟨hal-03876188⟩